Drug shown to significantly improve survival in men with metastatic prostate cancer

June 6, 2011

The final survival analysis of an international study of a new drug for prostate cancer has found an even greater median survival benefit than previously reported, and has established a new class of treatment for men with metastatic prostate cancer. In addition, researchers are exploring a potential biomarker of response to treatment in general. The results were presented today by Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center at the 2011 Annual Meeting of the American Society of Clinical Oncology. The drug, abiraterone acetate (trade name Zytiga) was recently approved by the FDA.

"In addition to demonstrating that abiraterone acetate prolongs lives, this treatment also offers men with metastatic castration resistant disease after chemotherapy a new treatment option at a point in the illness where hormonal agents are typically not considered. The survival benefit demonstrated that these tumors are not uniformly resistant to hormonal therapy. Of additional interest is that we have a potential new biomarker for measuring a drug's effectiveness in ," said Dr. Scher.

Interest in the clinical relevance of (CTC) is longstanding, but has increased significantly with the availability of assays and devices to detect, count and characterize these cells. Circulating tumor cells (CTC) represent approximately one cell in a billion of those found in the blood stream. According to Dr. Scher, "a critical unmet need in patient management and drug development in prostate cancer is for reliable indicators of . This is because there are no standards to assess disease in bone, the most common site of spread, and while are used to guide patient management, there are situations in which the patient may be benefitting from treatment when levels are going up, and not benefitting when they are going down."

In this study, the demonstrated of abiraterone acetate enabled Dr. Scher and his team to begin the process of examining the question of a surrogate endpoint in clinical trials. Surrogate endpoints are biomarkers that can be "substituted" or used in place of a clinical endpoint. "A critical goal of our research is to identify an early endpoint that can be used as a surrogate for survival in a clinical trial," said Dr. Scher. "A surrogate endpoint for survival that has been qualified by the FDA, can be used in New Drug Applications and enable the accelerated approval of drugs," he added.

The randomized, double blind, placebo controlled trial included 1195 men with metastatic prostate cancer whose disease had progressed after docetaxel-based chemotherapy. Patients were randomized 2:1 to receive prednisone with either the experimental drug called abiraterone acetate or placebo. In this final analysis, after following up with patients after 20.2 months on treatment, overall survival for the abiraterone acetate group was 15.8 months versus 11.2 months for the placebo group. In September 2010, the data monitoring committee recommended unblinding the study to allow the placebo group to switch to abiraterone acetate. Interim results of the trial were published on May 26, 2011 in The New England Journal of Medicine and found that in patients followed for a little more than 12 months, overall survival for the abiraterone acetate group was 14.8 months versus 10.9 months for the placebo plus prednisone group. In this final analysis, presented at ASCO, the difference in median overall between the two groups improved from 3.9 to 4.6 months. In April 2011, abiraterone acetate was approved by the FDA for use in men with metastatic prostate cancer who have failed on chemotherapy.

Explore further: Drug treatment extends lives of men with prostate cancer

Related Stories

Drug treatment extends lives of men with prostate cancer

May 26, 2011
(Medical Xpress) -- A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time.

ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients

June 2, 2011
Metastatic prostate cancer patients who received an investigational vaccine made from their own frozen immune cells lived 10 months longer than those not treated with it, according to data being presented by researchers from ...

Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer

April 21, 2011
A Data and Safety Monitoring Committee (DSMC) has determined that patients in a phase III clinical trial given atrasentan in addition to a standard chemotherapy regimen for advanced prostate cancer did not have longer survival ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.